Searched for
SUVN 502
Suven Life Sciences breathes new life into drug discovery plansThe funding to keep his drug discovery pursuits alive may not be a problem, as Jasti in December last year sold his profitable contract dev...- Suven Life Sciences rallies 11%. Here's whyShares of Suven Life have soared about 25 per cent in the last one month. In the last one year, the company has delivered over 65 per cent ...
- Kotak Securities re-initiates buy on Suven Life Sciences, target price Rs 445Buy Suven Life Sciences Ltd. at a price target of Rs 445.0 .
- The growth for the year will normalise around 20%: Venkat Jasti, Chairman & CEO, Suven Life Science"Speciality chemicals has more or less reached the top. It has reached saturation level and the growth will be 3 per cent to 5 per cent ove...
- Presence of many early stage projects affected sales and margins: Venkat Jasti, Suven Life CEOIn an interview with ET Now, Venkat Jasti, Suven Life CEO, attributed the drop in sales and margins in quarterly results to presence of man...
- Suven Life Sciences could be a dark horse: Devang MehtaTypically, it is a pharma stock which enjoys very high margins. In addition, it has a huge monetisation opportunity for one of its molecule...
- Suven Life Sciences Q1 net profit up by 137%Suven Life Sciences Ltd net profit rise by 137% for Q1. Company to go ahead with amalgamation of Suven Nishtaa Pharma Pvt Ltd with Suven Li...
- Suven gets four new drug molecule patents in four countriesSuven Life Sciences Ltd gets four product patents one each from Australia, Canada, Korea and New Zealand for their new drug molecules (New ...
- Suven Life Sciences Ltd posts 2.46 pc increase in Q1 net profitSuven's revenue grew by 23.48 per cent to Rs 44.8 crore in the June quarter as against Rs 36.3 crore in the same period last year, a compan...
- Suven Life drug candidate clears toxic tests; stock upSuven Life Sciences clinical drug candidate SUVN- 502, meant for treatment of Alzheimer’s disease and Schizophrenia, has successfully compl...
- Suven in talks with global drug makers for licensing deal: CEODrug maker Suven Life Sciences is in talks with four global pharma majors for a licensing deal for its Alzheimer drug SUVN-502, a top compa...
- Suven Life Sciences in demand on Alzheimer drug dealShares of Suven Life Sciences touched a 52-week high after the firm said it was in talks with four global pharmaceutical firms, which have ...
- Stocks to watch: HCL Tech, Lanco Infra, Ranbaxy, Bharti Airtel, NTPC, Suven Life SciencesCrude oil prices slipped lower Tuesday on account of profit booking after a six days rise. US crude futures for October fell to $73.84 per ...
- Suven to raise funds for phase II trials of Alzheimer’s moleculeSuven Life Sciences’ molecule for Alzheimer’s disease will soon enter phase II trials.
- Suven all set to raise funds for Alzheimer trialsSuven Life Sciences' molecule for Alzheimer's disease will soon enter phase two trials. Hyderabad-based contract research company is in pro...
- Suven starts phase I clinical trials of SUVN-502Pharmaceutical firm Suven Life Sciences today said it has commenced phase I clinical trials of SUVN-502, used in the treatment of Alzheimer...
- Suven gets European patent for its clinical candidate SUVN-502Pharmaceutical firm Suven Life Sciences on Monday said it has received European product patent for its clinical candidate SUVN-502, valid u...
- Suven Life Sciences receives first US product patentSuven Life Sciences has received its first product patent from the US Patent Office.
- Suven Life gets patents for 2 neurodegenerative NCEsSuven Life Sciences' two chemical entities for treatment of disorders associated with neurodegenerative diseases have received patents from...
- Suven files investigational new drug applicationPharma firm Suven Life Sciences said on Thursday that it has filed an application with Drug Control General of India to get approval for co...
Load More
